Patents by Inventor Victoria Feher
Victoria Feher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230295171Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.Type: ApplicationFiled: January 12, 2023Publication date: September 21, 2023Inventors: Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Masashi Takahashi, Christopher Smith, Qing Dong, Victoria Feher, Zhe Nie
-
Publication number: 20220306634Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.Type: ApplicationFiled: June 21, 2019Publication date: September 29, 2022Inventors: Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Masashi Takahashi, Christopher Smith, Qing Dong, Victoria Feher, Zhe Nie
-
Patent number: 11344559Abstract: The present disclosure relates to PI3K? inhibitors and methods of their use.Type: GrantFiled: June 25, 2020Date of Patent: May 31, 2022Assignee: The Regents of the University of CaliforniaInventors: Judith Varner, Rommie Amaro, Megan Kaneda, Robert Malmstrom, Victoria Feher
-
Publication number: 20200405730Abstract: The present disclosure relates to PI3K? inhibitors and methods of their use.Type: ApplicationFiled: June 25, 2020Publication date: December 31, 2020Inventors: Judith Varner, Rommie Amaro, Megan Kaneda, Robert Malmstrom, Victoria Feher
-
Publication number: 20180141951Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.Type: ApplicationFiled: August 21, 2017Publication date: May 24, 2018Inventors: Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Masashi Takahashi, Christopher Smith, Qing Dong, Victoria Feher, Zhe Nie
-
Publication number: 20150336964Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.Type: ApplicationFiled: July 31, 2015Publication date: November 26, 2015Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Christopher Smith, Masashi Takahashi, Qing Dong, Victoria Feher, Zhe Nie
-
Patent number: 9181255Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.Type: GrantFiled: December 17, 2010Date of Patent: November 10, 2015Assignee: Takeda Pharmaceutical Company LimitedInventors: Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Zhe Nie, Christopher Smith, Masashi Takahashi, Qing Dong, Victoria Feher
-
Patent number: 9108970Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.Type: GrantFiled: May 2, 2013Date of Patent: August 18, 2015Assignee: Takeda Pharmaceutical Company LimitedInventors: Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Christopher Smith, Masashi Takahashi, Qing Dong, Victoria Feher, Zhe Nie
-
Publication number: 20130245031Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.Type: ApplicationFiled: May 2, 2013Publication date: September 19, 2013Applicant: Takeda Phamaceutical Company LimitedInventors: Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Christopher Smith, Massashi Takahashi, Qing Dong, Victoria Feher, Zhi Nie
-
Patent number: 8440689Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.Type: GrantFiled: December 17, 2010Date of Patent: May 14, 2013Assignee: Takeda Pharmaceutical Company LimitedInventors: Yasuyoshi Arikawa, Qing Dong, Victoria Feher, Benjamin Jones, Betty Lam, Zhe Nie, Christopher Smith, Masashi Takahashi
-
Publication number: 20130116260Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.Type: ApplicationFiled: December 17, 2010Publication date: May 9, 2013Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Yasuyoshi Arikawa, Benjamin Jones, Betty Lam, Zhe Nie, Christopher Smith, Masashi Takahashi, Qing Dong, Victoria Feher
-
Patent number: 8318727Abstract: Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.Type: GrantFiled: December 7, 2010Date of Patent: November 27, 2012Assignee: Takeda Pharmaceutical Company LimitedInventors: Sheldon X Cao, Victoria Feher, Takashi Ichikawa, Benjamin Jones, Stephen W. Kaldor, Andre A. Kiryanov, Yan Liu, Chrisopher McBride, Srinivasa Ready Natala, Zhe Nie, Jeffrey A. Stafford, Betty Lam
-
Publication number: 20110201818Abstract: Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.Type: ApplicationFiled: September 24, 2008Publication date: August 18, 2011Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Takashi Ichikawa, Benjamin Jones, Andre A. Kiryanov, Christopher McBride, Srinivasa Reddy Natala, Zhe Nie, Sheldon X. Cao, Betty Lam, Victoria Feher, Stephen W. Kaldor, Yan Liu, Jeffrey A Stafford
-
Publication number: 20110152273Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.Type: ApplicationFiled: December 17, 2010Publication date: June 23, 2011Applicant: Takeda Pharmaceutical Company LimitedInventors: Yasuyoshi Arikawa, Qing Dong, Victoria Feher, Benjamin Jones, Betty Lam, Zhe Nie, Christopher Smith, Masashi Takahashi
-
Publication number: 20110082111Abstract: Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.Type: ApplicationFiled: December 7, 2010Publication date: April 7, 2011Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Sheldon X. Cao, Victoria Feher, Takashi Ichikawa, Benjamin Jones, Stephen W. KALDOR, Andre A. KIRYANOV, Betty Lam, Yan Liu, Christopher McBride, Srinivasa Reddy Natala, Zhe Nie, Jeffrey A. Stafford
-
Publication number: 20100204471Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.Type: ApplicationFiled: October 22, 2007Publication date: August 12, 2010Applicant: Takeda Pharmaceutical Company LimitedInventors: Qing Dong, Victoria Feher, Stephen W. Kaldor, Naoki Tomita
-
Publication number: 20090291938Abstract: Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.Type: ApplicationFiled: November 19, 2008Publication date: November 26, 2009Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Sheldon X. Cao, Victoria Feher, Takashi Ichikawa, Benjamin Jones, Stephen W. Kaldor, Andre A. Kiryanov, Betty Lam, Yan Liu, Christopher McBride, Srinivasa Reddy Natala, Zhe Nie, Jeffrey A. Stafford
-
Publication number: 20090281092Abstract: Compounds of the following formula are provided for use with kinases: wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.Type: ApplicationFiled: September 24, 2008Publication date: November 12, 2009Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Sheldon X. Cao, Victoria Feher, Takashi Ichikawa, Benjamin Jones, Stephen W. Kaldor, Andre A. Kiryanov, Betty Lam, Yan Liu, Christopher McBride, Srinivasa Reddy Natala, Zhe Nie, Jeffrey A. Stafford
-
Publication number: 20080125437Abstract: Compounds, pharmaceutical compositions, kits and methods are provided for use with MEK that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.Type: ApplicationFiled: October 22, 2007Publication date: May 29, 2008Inventors: Qing DONG, Victoria Feher, Stephen W. Kaldor, Naoki Tomita